HI,
In answer to you two questions:
Question 1
In my experience, providers who routinely perform penile enhancement are all injecting into essentially the same plane. This is a potential space that sits above Buck’s fascia and below the more superficial penile fascia. That plane is chosen deliberately because:
Injecting too superficially (dermis or above superficial fascia) can lead to a pillowy or lumpy appearance.
Injecting into this deeper fascial plane helps the filler stay contained, distribute evenly, and smooth out over time.
When a cannula is used, it naturally finds this plane because it represents the path of least resistance between fascial layers. Once filler is placed there, it does not have the mechanical force to migrate toward the abdomen. Fascia behaves like two thin, tough sheets stuck together—once separated and filled, the material cannot continue dissecting upward on its own.
True filler migration is largely overstated online. What is often labeled as “migration” is usually overfilling or poor aesthetic judgment, not actual movement of filler. In reality, filler—regardless of type—does not travel more than a few millimeters from where it is placed, and when injected in the correct fascial plane, migration toward the abdomen essentially does not occur.
Bottom line: The difference in described planes is largely semantic. Experienced injectors are working in the same anatomical space, and migration in the scenario you describe is not a meaningful risk.
Question 2
The risk of biofilm formation is very low, even in the early post-procedure period, and becomes negligible once healing is complete.
Early on, the injection site contains blood products, fibrin, and inflammatory mediators that actually have antimicrobial properties.
PMMA microspheres are manufactured in FDA-regulated facilities and are specifically designed not to promote bacterial adherence.
After encapsulation—which occurs over weeks to months—the theoretical risk drops even further. In decades of clinical use of fillers in multiple areas of the body, true, proven biofilm infections are extraordinarily rare. What is sometimes mistaken for “biofilm” is actually an inflammatory reaction triggered by an unrelated systemic infection or immune stimulus (e.g., viral illness, dental work, vaccines). That is a different mechanism and not an ongoing infection.
Your festival example with a superficial skin cut and staph exposure does not translate into a lifelong risk after
PMMA. Once healed, you do not need to avoid normal life activities.
Bottom line: Follow standard aftercare, keep the area clean during initial healing, and once healed, biofilm risk is essentially a non-issue.
Dr. S
